Litcius/Paper detail

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo, Ana S. Gonzalez‐Reiche, Sadaf Aslam, Adriana van de Guchte, Zenab Khan, Ajay Obla, Jayeeta Dutta, Harm van Bakel, Judith A. Aberg, Adolfo García‐Sastre, Gunjan L. Shah, Tobias M. Hohl, Genovefa A. Papanicolaou, Miguel‐Angel Perales, Kent A. Sepkowitz, N. Esther Babady, Mini Kamboj

2020New England Journal of Medicine437 citationsDOIOpen Access PDF

Abstract

Shedding of SARS-CoV-2 after Immunosuppression The prolonged contagious period after viral infection in immunocompromised patients may affect how long precautions will be necessary to reduce furthe...

Topics & Concepts

ImmunosuppressionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Viral sheddingCoronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakVirologyCancerCancer therapyImmunologyIntensive care medicineVirusDiseaseInfectious disease (medical specialty)Internal medicineOutbreakCOVID-19 and healthcare impactsCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer | Litcius